- Home
- QIPT vs KOD Comparison
QIPT vs KOD Comparison
Compare QIPT & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QIPT | KOD |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.7M | 795.5M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | QIPT | KOD |
|---|---|---|
| Price | $3.53 | $29.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $3.83 | ★ $22.67 |
| AVG Volume (30 Days) | ★ 1.1M | 909.3K |
| Earning Date | 12-15-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,359,000.00 | N/A |
| Revenue This Year | $28.30 | N/A |
| Revenue Next Year | $1.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.35 | $1.92 |
| 52 Week High | $3.54 | $31.18 |
Technical Indicators
Market Signals| Indicator | QIPT | KOD |
|---|---|---|
| Relative Strength Index (RSI) | 85.36 | 64.85 |
| Support Level | $2.40 | $25.44 |
| Resistance Level | $3.54 | $31.18 |
| Average True Range (ATR) | 0.05 | 2.23 |
| MACD | 0.06 | 0.34 |
| Stochastic Oscillator | 99.12 | 80.73 |
Price Performance
Historical ComparisonAbout QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.